CN110101756A - 一种可改善血液微循环障碍和骨质疏松症的天然组合物及其制备方法 - Google Patents
一种可改善血液微循环障碍和骨质疏松症的天然组合物及其制备方法 Download PDFInfo
- Publication number
- CN110101756A CN110101756A CN201910338442.XA CN201910338442A CN110101756A CN 110101756 A CN110101756 A CN 110101756A CN 201910338442 A CN201910338442 A CN 201910338442A CN 110101756 A CN110101756 A CN 110101756A
- Authority
- CN
- China
- Prior art keywords
- extract
- osteoporosis
- blood
- bone
- natural composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 68
- 239000008280 blood Substances 0.000 title claims abstract description 68
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 57
- 230000004089 microcirculation Effects 0.000 title claims abstract description 48
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000000284 extract Substances 0.000 claims abstract description 135
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 50
- 240000000759 Lepidium meyenii Species 0.000 claims abstract description 27
- 235000000421 Lepidium meyenii Nutrition 0.000 claims abstract description 27
- 235000012902 lepidium meyenii Nutrition 0.000 claims abstract description 27
- 210000000582 semen Anatomy 0.000 claims abstract description 22
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 19
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 19
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 19
- 229940010454 licorice Drugs 0.000 claims abstract description 19
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 18
- 230000001976 improved effect Effects 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 12
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 12
- 230000037182 bone density Effects 0.000 claims abstract description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000001301 oxygen Substances 0.000 claims abstract description 7
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 6
- 239000011707 mineral Substances 0.000 claims abstract description 6
- 244000061520 Angelica archangelica Species 0.000 claims abstract 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 53
- 235000019441 ethanol Nutrition 0.000 claims description 31
- 238000000605 extraction Methods 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 229940119485 safflower extract Drugs 0.000 claims description 20
- 241000202807 Glycyrrhiza Species 0.000 claims description 18
- 239000012153 distilled water Substances 0.000 claims description 16
- 238000010992 reflux Methods 0.000 claims description 16
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 12
- 241000180649 Panax notoginseng Species 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 11
- 241001148782 Davallia Species 0.000 claims description 10
- 239000013049 sediment Substances 0.000 claims description 10
- 244000144730 Amygdalus persica Species 0.000 claims description 9
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- DBOVHQOUSDWAPQ-UHFFFAOYSA-N (4aS)-6c-[O2-(3,5,3'-trihydroxy-biphenyl-2-carbonyl)-beta-D-glucopyranosyloxy]-5t-vinyl-(4ar)-4,4a,5,6-tetrahydro-3H-pyrano[3,4-c]pyran-1-one Natural products OC1C(O)C(CO)OC(OC2C(C3C(C(OCC3)=O)=CO2)C=C)C1OC(=O)C1=C(O)C=C(O)C=C1C1=CC=CC(O)=C1 DBOVHQOUSDWAPQ-UHFFFAOYSA-N 0.000 claims description 4
- BZXINCMCFVKGKB-UHFFFAOYSA-N Amarogentin Natural products OCC1OC(OC2OC=C3C(CCOC3=O)C2C=C)C(OC(=O)c4cc(O)cc(O)c4c5cccc(O)c5)C(O)C1O BZXINCMCFVKGKB-UHFFFAOYSA-N 0.000 claims description 4
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims description 4
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 4
- DBOVHQOUSDWAPQ-WTONXPSSSA-N amarogentin Chemical compound O([C@H]1[C@H](O[C@H]2[C@@H]([C@H]3C(C(OCC3)=O)=CO2)C=C)O[C@@H]([C@H]([C@@H]1O)O)CO)C(=O)C1=C(O)C=C(O)C=C1C1=CC=CC(O)=C1 DBOVHQOUSDWAPQ-WTONXPSSSA-N 0.000 claims description 4
- 229930003944 flavone Natural products 0.000 claims description 4
- 235000011949 flavones Nutrition 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 4
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 4
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 4
- 239000001685 glycyrrhizic acid Substances 0.000 claims description 4
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 4
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 4
- MYBAONSAUGZRAX-UBQYYSLZSA-N Notoginsenoside Fe Chemical class C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O MYBAONSAUGZRAX-UBQYYSLZSA-N 0.000 claims description 3
- 239000006286 aqueous extract Substances 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 3
- 238000004821 distillation Methods 0.000 claims description 3
- 150000002212 flavone derivatives Chemical class 0.000 claims description 3
- 238000002137 ultrasound extraction Methods 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 2
- 238000002386 leaching Methods 0.000 claims description 2
- 230000004888 barrier function Effects 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 13
- 239000011575 calcium Substances 0.000 abstract description 13
- 229910052791 calcium Inorganic materials 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 13
- 239000003814 drug Substances 0.000 abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 7
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract description 6
- 210000000963 osteoblast Anatomy 0.000 abstract description 6
- 239000011574 phosphorus Substances 0.000 abstract description 6
- 229910052698 phosphorus Inorganic materials 0.000 abstract description 6
- 210000004204 blood vessel Anatomy 0.000 abstract description 5
- 210000002997 osteoclast Anatomy 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- 230000002503 metabolic effect Effects 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 241000125175 Angelica Species 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 10
- 210000000689 upper leg Anatomy 0.000 description 7
- 210000001772 blood platelet Anatomy 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000004097 bone metabolism Effects 0.000 description 4
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 4
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 3
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 3
- 206010017076 Fracture Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 210000004623 platelet-rich plasma Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 description 2
- DYQVDISPPLTLLR-HJQYTNQXSA-N Carthamin Natural products CC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@]2(O)C(=C(C=C/3C(=O)C(=C(O)[C@](O)([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C3=O)C(=O)C=Cc5ccc(O)cc5)C(=O)C(=C2O)C(=O)C=Cc6ccc(O)cc6)O DYQVDISPPLTLLR-HJQYTNQXSA-N 0.000 description 2
- 240000001008 Dimocarpus longan Species 0.000 description 2
- 235000000235 Euphoria longan Nutrition 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 206010030247 Oestrogen deficiency Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003262 anti-osteoporosis Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- OQUFOZNPBIIJTN-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;sodium Chemical compound [Na].OC(=O)CC(O)(C(O)=O)CC(O)=O OQUFOZNPBIIJTN-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 description 1
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 101710100588 Erythroid transcription factor Proteins 0.000 description 1
- 102100031690 Erythroid transcription factor Human genes 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 101710082961 GATA-binding factor 2 Proteins 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 206010020100 Hip fracture Diseases 0.000 description 1
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 1
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 1
- 101001086210 Homo sapiens Osteocalcin Proteins 0.000 description 1
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100031475 Osteocalcin Human genes 0.000 description 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102000001712 STAT5 Transcription Factor Human genes 0.000 description 1
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003023 adrenocorticotropic effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000004380 ashing Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 229940003871 calcium ion Drugs 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000000066 endothelium dependent relaxing factor Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- -1 flavone compound Chemical class 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005096 hematological system Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000004072 osteoblast differentiation Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012783 reinforcing fiber Substances 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
- A61K36/126—Drynaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种可改善血液微循环障碍和骨质疏松症的天然组合物及其制备方法,所述天然组合物由三七提取物10~20份、桃仁提取物10~20份、骨碎补提取物5~15份、红花取物10~20份、当归提取物10~20份、玛咖提取物10~20份和甘草提取物5~15份组成。本发明的药物组合物,含多种有效成分,针对不同的靶点和信号通路协同作用,使各有效成分相互配合,可扩张血管,降低血液粘度,提高血液流动性,改善血液微循环障碍,促进钙、氧等营养物质的运输及吸收进而改善成骨细胞和破骨细胞的代谢紊乱状态,提高骨密度、骨钙和骨磷等骨矿物质含量,达到治疗骨质疏松症效果。本组合物采用天然药材为原料,多成分多靶点协同作用,标本兼治且无毒副作用。
Description
技术领域
本发明属于天然组合物技术领域,具体涉及一种改善血液微循环障碍而改善型骨质疏松症的天然组合物及其制备方法。
背景技术
骨质疏松症(osteoporosis,OP)是一种全身性的骨代谢疾病,可发生于任何年龄,但多见于绝经后女性和老年男性,主要特征为骨量低,骨组织微结构损坏,导致骨脆性增加,易发生骨折。骨质疏松性骨折的危害巨大,是老年患者致残和致死的主要原因之一。发生髋部骨折后1年之内,20%患者会死于各种并发症,约50%患者致残,生活质量明显下降。骨质疏松症及骨折的治疗和护理,需要投入大量的人力、物力和财力,给患者家庭和社会造成沉重的负担。随着人口老龄化日趋严重,预防和治疗骨质疏松,减少骨质疏松症引起骨折的发生已成为我国面临的重要健康需求。
现代医学关于骨质疏松症发病机制提出了衰老、雌激素和骨内高压等学说,这些学说均与血液微循环障碍存在一定关系。老年患者具有“多虚多瘀”的体质特点,衰老所引起的血液微循环障碍直接影响骨质疏松症患者的骨代谢,是导致骨质疏松的主要原因之一。雌激素缺乏会增加血脂浓度,导致血管内皮舒张因子(NO)和血管内皮收缩因子(ET)相互拮抗失调,导致微循环血管舒缩功能紊乱,出现血液微循环障碍,而雌激素缺乏是女性发生骨质疏松症的主要因素。此外,骨质疏松症患者骨内高压与血液微循环障碍也密切相关,骨小梁内微血管的激发损伤所引起的血液微循环障碍必将使骨内压升高,造成血液循环中氧、钙等营养物质不能正常进入骨内,骨细胞代谢发生异常,导致骨重建失衡而引起骨质疏松。采用活血化瘀天然药用资源可通过改善骨内微循环障碍,促进氧、钙等营养物质进入骨骼,使骨代谢恢复正常,以有效改善骨质疏松。有必要针对骨质疏松症患者从改善微循环障碍角度开发新的健康产品
目前治疗骨质疏松常用的药物主要有雌激素、双膦酸盐、地诺赛麦等骨吸收抑制剂或骨形成促进剂,虽然有一定疗效,但不良反应较大。骨质疏松症的预防与治疗是一个漫长的过程,天然药材组合物具有多成分、多靶点,配伍适中安全、协同促进增效等特点,更加切合骨质疏松症以预防为主,防治结合的防治要求,使其在防治骨质疏松症方面发挥着巨大的作用。而采用活血化瘀天然药用资源更可通过改善骨内微循环障碍,促进氧、钙等营养物质进入骨骼,使骨代谢恢复正常,对于抗骨质疏松健康产品的开发具有重要意义。
发明内容
有鉴于此,本发明提供了一种改善血液微环境障碍而改善骨质疏松症的天然组合物及其制备方法。本发明采用天然药用资源,含多种有效成分,针对不同的靶点和信号通路协同作用,使各有效成分相互配合,可扩张血管,降低血液粘度,提高血液流动性,改善血液微循环障碍,促进钙、氧等营养物质的运输及吸收进而改善成骨细胞和破骨细胞的代谢紊乱状态,提高骨密度、骨钙和骨磷等骨矿物质含量,对治疗骨质疏松症有良好效果。
本发明第一方面提供了一种改善血液微环境障碍而改善骨质疏松症的天然组合物,组分包括:以质量百分比计,三七提取物10-20%、桃仁提取物10-20%、骨碎补提取物5-15%、红花提取物10-20%、当归提取物10-20%、玛咖提取物10-20%和甘草提取物5-15%。
上述天然组合物中,其原料药的主要功效活性如下:
三七对中枢神经系统、心血管系统、血液系统、免疫系统等方面均有较强的生理活性,能缩短凝血时间,促进血液流动,增加血流量,抗心律失常,并且具有抗高血压、抗炎、镇痛、提高免疫力、抗肿瘤和滋补强壮的作用。其含有的三七总苷能促进成骨细胞分泌IGF-1,抑制其分泌IL-6,从而促进成骨细胞增长,抑制破骨细胞增殖;还能抑制血小板黏附和聚集,诱导造血细胞GATA-1和GATA-2转录调控蛋白合成增加,增高其与上游调控区的启动子和增强子结合的活性进而调控造血细胞增殖、分化,改善微循环;促进金属硫蛋白(MT)合成,减轻组织缺氧状态,促进血管生成,改善骨组织内血液微循环障碍,促进骨组织内代谢平衡,进而发挥抗骨质疏松作用。
骨碎补中的活性成分黄酮类化合物能促进成骨细胞内ALP形成,介导组织蛋白酶K在破骨细胞中的成熟和转运;抑制肿瘤坏死因子TNF-α、白细胞介素IL-6水平,促进IL-4分泌;并可减少血小板的聚集性,使血管扩张,血流加快,血细胞团聚减轻,具有改善血液流变性、微循环障碍的作用,可有效促进骨折愈合,防止骨质疏松。
红花中的有效成分红花黄色素能通过提高Runx2、OCN、SOX2等成骨分化水平,延长凝血酶原时间,拮抗血小板激活因子与血小板受体的结合,抑制中性粒细胞聚集、黏附及超氧化物的产生,并通过抑制中枢加压反射、激动H1受体、抑制肾素、血管紧张和直接扩张外周血管改善血液黏稠度,降低血压,改善骨组织供血,促进骨形成。
当归中的主要活性成分当归多糖通过作用于JAK2和STAT5信号转导通路促进促红细胞生成素生成,能增加外周血红细胞、白细胞、血红蛋白及骨髓有核细胞数,促进血液形成,能调节骨髓造血干细胞表面黏附分子表达,降低粘附力,抑制Wnt/β-catenin信号通路的过度激活,调节骨代谢平衡,改善骨质疏松。
桃仁中的活性成分苦杏仁苷能增强纤维蛋白的溶解,抑制血清中磷酸肌酸激酶、乳酸脱氢酶的升高,降低栓塞面积,并能能扩张血管、增加器官血流量,抑制血小板聚集,抗凝血,提高纤溶蛋白酶活性,改善血液流变性并促进微循环,促进钙离子吸收进入骨骼中沉淀,促进骨骼强壮。
玛咖中的主要活性物质玛咖酰胺能刺激雌激素的生成,降低血卵泡生成激素、甲状腺素和促肾上腺激素和皮质醇水平,促进骨形成,抑制骨吸收,从而增加骨密度,有效改善骨质疏松;
甘草的主要活性成分甘草酸可促进碱性磷酸酶、雌二醇的分泌,减少骨的重吸收,促进骨钙及骨矿物形成,造成骨盐沉积的增加而拮抗骨质疏松。
优选的,所述三七提取物中三七总苷含量≥100mg/g;所述桃仁提取物中苦杏仁苷含量≥200mg/g;所述骨碎补提取物中总黄酮含量≥50mg/g;所述红花提取物中红花黄色素含量≥50mg/g;所述当归提取物中当归多糖含量≥200mg/g;所述玛咖提取物中玛咖酰胺含量≥40mg/g;所述甘草提取物中甘草酸含量≥400mg/g。
本发明第二方面提供了上述可改善血液微循环障碍和骨质疏松症的天然组合物的制备方法,步骤包括:以三七、桃仁、骨碎补、红花、当归、玛咖和甘草为原料,对原料分别进行提取,将提取得到的三七提取物、桃仁提取物、骨碎补提取物、红花提取物、当归提取物、玛咖提取物和甘草提取物按比例混合。
优选的,所述三七提取物的提取方法包括:取干燥三七,粉碎,与65~75%乙醇以质量体积比1:5~10的比例混合,浸润22~26h,70-90℃回流提取3~5小时,减压浓缩至浸膏,将所得浸膏干燥,即得三七提取物。
更加优选的,在上述三七提取物的提取过程中,所述干燥三七粉碎后与70%乙醇以质量体积比1:5~10的比例混合,浸润24h。
优选的,所述桃仁提取物的提取方法包括:取桃仁,粉碎,与乙醇以质量体积比1:5~10的比例混合,浸润2~4h,60-80℃回流提取4~5小时,减压浓缩至浸膏,所得浸膏干燥后即为桃仁提取物。
更加优选的,在上述桃仁提取物的提取过程中,所述桃仁粉碎后与乙醇以质量体积比1:5~10的比例混合,浸润3h。
优选的,所述骨碎补提取物的提取方法包括:取干燥的骨碎补,粉碎,与蒸馏水以质量体积比1:10~20的比例混合,80~90℃浸泡提取4~8小时,水提取液减压浓缩至浸膏,浸膏与乙醇以质量体积比1:5~8的比例混合,收集沉淀物,沉淀物进行干燥后即可得骨碎补提取物。
更加优选的,在上述骨碎补提取物的提取过程中,所述浸膏与体积百分数95%乙醇以质量体积比1:5~8的比例混合后收集沉淀物。
优选的,所述红花提取物的提取方法包括:取红花,与蒸馏水以质量体积比1:30~40的比例混合,调节pH至2~4,70-90℃回流提取2~4小时,过滤,滤液减压蒸馏浓缩至浸膏状态,浸膏与乙醇以质量体积比1:5~10的比例混合,以1800~2200r/min离心8~12min,所得沉淀物真空干燥,即得红花提取物。
更加优选的,在上述红花提取物的提取过程中,所述红花与蒸馏水混合后调节pH至3。
更加优选的,在上述红花提取物的提取过程中,所述浸膏与乙醇混合后以2000r/min离心10min。
优选的,所述当归提取物的提取方法包括:取干燥的当归适量,粉碎,与水以质量体积比1:5~10的比例混合,70-90℃回流提取3~5小时,减压浓缩,加入乙醇至醇浓度为60~70%,放置22~26h抽滤后干燥即得当归提取物。
更加优选的,在上述当归提取物的提取过程中,减压浓缩后加入体积百分数95%乙醇至醇浓度为65%,放置24h后抽滤、干燥。
优选的,所述玛咖提取物的提取方法包括:取干燥的玛咖,与乙醇以质量体积比1:5~10的比例混合,超声提取2~4小时,醇提取液45~55℃减压浓缩至浸膏,浸膏干燥即得玛咖提取物。
更加优选的,在上述玛咖提取物的提取过程中,所述醇提取液于50℃减压浓缩至浸膏。
优选的,所述甘草提取物的提取方法包括:取干燥的甘草,与蒸馏水以质量体积比1:9~11的比例混合,88~92℃回流提取3.5~4.5小时,提取液浓缩至原体积的1/4~1/6,过滤,滤液加浓盐酸调pH至2~4,静置7~9小时,过滤,滤渣用蒸馏水洗涤,滤渣干燥即得甘草提取物。
更加优选的,在上述甘草提取物的提取过程中,所述干燥的甘草与蒸馏水以质量体积比1:10的比例混合,90℃回流提取4小时,提取液浓缩至原体积的1/5,过滤,滤液加浓盐酸调pH至3,静置8小时,过滤,滤渣用适量蒸馏水洗涤两次,滤渣干燥即得甘草提取物。
本发明第三方面提供了上述可改善血液微循环障碍和骨质疏松症的天然组合物在制备骨质疏松症治疗药物中的应用,所述骨质疏松症治疗药物用于降低血液粘度、提高血液流动性,提高骨密度、骨矿物质含量。
与现有技术相比,本发明的有益效果是:本发明提供的可改善血液微循环障碍和骨质疏松症的天然组合物,可降低血液粘度,提高血液流动性,改善血液微循环障碍,促进钙、氧等营养物质的运输及吸收进而改善成骨细胞和破骨细胞的代谢紊乱状态,提高骨密度、骨钙和骨磷等骨矿物质含量,有效治疗骨质疏松;本发明提供的可改善血液微循环障碍和骨质疏松症的天然组合物,制作原料均为天然药用资源,无任何化学添加剂,安全无公害;且该天然组合物多成分多靶点协同作用,标本兼治,效果显著且无毒副作用
具体实施方式
为了便于理解本发明,下文将结合实施例对本发明作更全面、细致地描述,但本发明的保护范围并不限于以下具体的实施例。
除非另有定义,下文中所使用的所有专业术语与本领域技术人员通常理解的含义相同。本文中所使用的专业术语只是为了描述具体实施例的目的,并不是旨在限制本发明的保护范围。
除非另有特别说明,本发明中用到的各种原材料、试剂、仪器和设备等,均可通过市场购买得到或者可通过现有方法制备得到。
实施例1
本实施例提供了一种可改善血液微循环障碍和骨质疏松症的天然组合物,原料包括:以重量百分比计,三七提取物20%、桃仁提取物15%、骨碎补提取物5%、红花提取物20%、当归提取物15%、玛咖提取物15%和甘草提取物10%。
所述三七提取物中三七总皂苷含量≥100mg/g,制备方法为:
取干燥三七适量,粉碎,与70%乙醇以质量体积比1:5的比例混合,浸润24h,80℃回流提取4小时,减压浓缩至浸膏,所得浸膏经干燥箱中干燥,即得三七提取物。
所述桃仁提取物中苦杏仁苷含量≥200mg/g,制备方法为:
取桃仁适量,粉碎,与乙醇以质量体积比1:6的比例混合,浸润3h,70℃回流提取5小时,减压浓缩至浸膏,所得浸膏干燥后即为桃仁提取物。
所述骨碎补提取物中总黄酮含量≥50mg/g,制备方法为:
取干燥的骨碎补适量,粉碎,与蒸馏水以质量体积比1:15的比例混合,85℃浸泡提取6小时,水提取液减压浓缩至浸膏,浸膏与95%乙醇以质量体积比1:8的比例混合,收集沉淀物,沉淀物进行干燥后即可得骨碎补提取物。
所述红花提取物中红花黄色素含量≥50mg/g,制备方法为:
取红花适量,与蒸馏水以质量体积比1:35的比例混合,调节pH至3,80℃回流提取3小时,滤布过滤,滤液减压蒸馏浓缩至浸膏状态,浸膏与乙醇以质量体积比1:8的比例混合,以2000r/min离心10min,所得沉淀物于真空干燥箱中干燥,即得红花提取物。
所述当归提取物中当归多糖含量≥200mg/g,制备方法为:
取干燥的当归适量,粉碎,与水以质量体积比1:8的比例混合,80℃回流提取4小时,减压浓缩,加入95%乙醇至醇浓度为65%,放置一天抽滤后干燥即得当归提取物。
所述玛咖提取物中玛咖酰胺含量≥40mg/g,制备方法为:
取干燥的玛咖适量,与乙醇以质量体积比1:8的比例混合,超声提取3小时,醇提取液50℃减压浓缩至浸膏,浸膏干燥即得玛咖提取物。
所述甘草提取物含甘草酸≥400mg/g,制备方法为:
取干燥的甘草适量,与蒸馏水以质量体积比1:10的比例混合,90℃回流提取4小时,提取液浓缩至原体积的1/5,过滤,滤液加浓盐酸调pH至3,静置8小时,过滤,滤渣用适量蒸馏水洗涤两次,滤渣干燥即得甘草提取物。
将上述提取得到的三七提取物、桃仁提取物、骨碎补提取物、红花提取物、当归提取物、玛咖提取物和甘草提取物按比例混合,即得改善血液微循环障碍并预防骨质疏松症的天然组合物。
实施例2
本实施例提供了一种可改善血液微循环障碍和骨质疏松症的天然组合物,原料包括:以重量百分比计,三七提取物20%、桃仁提取物20%、骨碎补提取物10%、红花提取物15%、当归提取物10%、玛咖提取物20%和甘草提取物5%。其制备方法与实施例1基本一致。
实施例3
本实施例提供了一种可改善血液微循环障碍和骨质疏松症的天然组合物,原料包括:以重量百分比计,三七提取物15%、桃仁提取物10%、骨碎补提取物15%、红花提取物20%、当归提取物15%、玛咖提取物10%和甘草提取物15%。其制备方法与实施例1基本一致。
实施例4
本实施例提供了一种可改善血液微循环障碍和骨质疏松症的天然组合物,原料包括:以重量百分比计,三七提取物10%、桃仁提取物10%、骨碎补提取物10%、红花提取物15%、当归提取物20%、玛咖提取物20%和甘草提取物15%。其制备方法与实施例1基本一致。
实施例5
本实施例提供了一种可改善血液微循环障碍和骨质疏松症的天然组合物,原料包括:以重量百分比计,三七提取物15%、桃仁提取物20%、骨碎补提取物15%、红花提取物10%、当归提取物10%、玛咖提取物20%和甘草提取物10%。其制备方法与实施例1基本一致。
对比例1
本对比例提供了一种天然组合物,原料为:以重量份数计,三七20份、桃仁15份、骨碎补5份、红花20份、当归15份、白芍15份和川芎10份。
按上述配比称取三七、桃仁、骨碎补、红花、当归、白芍和川芎后混合配药,研磨,加入与药物质量体积比为1:5的水后煎煮两次,将两次的煎煮液合并。
对比例2
本对比例提供了一种天然组合物,原料为:以重量份数计,三七20份、酸枣仁15份、骨碎补5份、玛咖20份、甘草15份、白芍15份和龙眼肉10份。
按上述配比称取三七、酸枣仁、骨碎补、玛咖、甘草、白芍和龙眼肉后混合配药,研磨,加入与药物质量体积比为1:5的水后煎煮两次,将两次的煎煮液合并。
实施例6
本实施例对实施例1-3和对比例1、2所提供的五组天然组合物的功效进行了测评,具体过程如下:
1.分组与给药
选取雌性SD大鼠为试验对象,体重180-200g,饲养于SPF级动物房,室温20-22℃,相对湿度为60%-70%,灯照周期为12h(7:00-9:00灯照,19:00-7:00黑暗),适应性喂养1周后,随机分为各实施例组、对比例组、模型组与空白组,每组10只。各组大鼠每日按常规方法分笼喂养,各实施例组和对比例组以3g/kg·BW剂量灌胃,模型组与空白组灌胃蒸馏水。
2.模型制作
各实施例组、对比例组与模型组每日皮下注射肾上腺素0.8mg//kg·BW,2h后将大鼠置于冰水浴中游泳4min,4h后再次皮下注射盐酸肾上腺素0.8mg//kg·BW,持续4周。空白组不做处理。
3.各实施例组对血液微循环障碍大鼠血液流变性能的影响
给药结束后,取血2ml用EDTA·K2抗凝,静置40min后,在全自动血液流变仪上进行全血黏度(高、中、低切)、血浆粘度等血液流变学参数的检测;取血约3.6ml,用3.8%枸橼酸钠抗凝(9:1),150g离心10min,分离出富血小板血浆(PRP),再以1500g离心10min,取上清液得到贫血小板血浆(PPP)。取PRP0.3ml于比浊管内,以PPP调透光度,二磷酸腺苷(ADP)作诱导剂(终浓度为2μmol/L),用血液凝聚仪检测PRP中血小板在5min内的最大聚集程度,测定血小板聚集率。采用SPSS 16.0软件进行数据分析,结果以x±s表示,组间比较采用单因素方差分析及最小显著差异法,P<0.05为差异有统计学意义。结果见表2。
表1各实施例天然组合物对大鼠血液流变性能的影响
注:a表示与模型组比较有显著差异;b表示与空白组比较有显著差异。
由表1可见,造模后,大鼠血液全血高切粘度、中切粘度、低切粘度、血浆粘度和血小板聚集率均增加,血液流动性减弱,出现血瘀症状,给予各实施例组合物后,血液流动性增加,血液微循环症状出现一定程度好转,各对比例组虽有一定效果但均弱于实施例组。
4.各实施例对大鼠骨质状况的影响
给药结束后处死大鼠,取大鼠双侧股骨小心剔除肌肉及其他组织,其中一侧股骨在双能X线骨密度仪上做骨密度扫描,测出骨密度(g/cm2),一侧股骨测骨长,110℃烘干1小时,称股骨重,再置马弗炉内800℃灰化6小时,灰化结束,冷却称灰重,用浓硝酸提取后测骨灰钙、磷含量。采用SPSS18.0软件进行数据分析,结果以x±s表示,组间比较采用单因素方差分析及最小显著差异法,P<0.05为差异有统计学意义。结果见表3、4。
表2各实施例对大鼠股骨骨密度及股骨骨指数的影响
注:a表示与模型组比较有显著差异;b表示与空白组比较有显著差异。
表3各实施例对大鼠股骨骨灰分、骨钙、骨磷的影响
注:a表示与模型组比较有显著差异;b表示与空白组比较有显著差异。
由表2和3可见,血液微循环障碍可造成大鼠骨密度、骨灰分、骨钙和骨磷含量下降,显示出骨质疏松症状,给予各实施例天然组合物后,可提高大鼠的骨骼质量,在一定程度上缓解骨质疏松症状。各对比例组虽有一定效果但均弱于实施例组。
由此可以看出,本发明提供的一种可改善血液微循环障碍和骨质疏松症的天然组合物可有效改善血液微循环障碍和骨质疏松症状。
尽管已描述了本发明的优选实施例,但本领域内的技术人员一旦得知了基本创造性概念,则可对这些实施例作出另外的变更和修改。所以,所附权利要求意欲解释为包括优选实施例以及落入本发明范围的所有变更和修改。
显然,本领域的技术人员可以对本发明进行各种改动和变型而不脱离本发明的精神和范围。这样,倘若本发明的这些修改和变型属于本发明权利要求及其等同技术的范围之内,则本发明也意图包含这些改动和变型在内。
Claims (10)
1.一种可改善血液微循环障碍和骨质疏松症的天然组合物,其特征在于:组分包括:以质量百分比计,三七提取物10-20%、桃仁提取物10-20%、骨碎补提取物5-15%、红花提取物10-20%、当归提取物10-20%、玛咖提取物10-20%和甘草提取物5-15%。
2.如权利要求1所述的可改善血液微循环障碍和骨质疏松症的天然组合物,其特征在于:所述三七提取物中三七总苷含量≥100mg/g;所述桃仁提取物中苦杏仁苷含量≥200mg/g;所述骨碎补提取物中总黄酮含量≥50mg/g;所述红花提取物中红花黄色素含量≥50mg/g;所述当归提取物中当归多糖含量≥200mg/g;所述玛咖提取物中玛咖酰胺含量≥40mg/g;所述甘草提取物中甘草酸含量≥400mg/g。
3.权利要求1或2所述的可改善血液微循环障碍和骨质疏松症的天然组合物的制备方法,其特征在于:以三七、桃仁、骨碎补、红花、当归、玛咖和甘草为原料,对原料分别进行提取,将提取得到的三七提取物、桃仁提取物、骨碎补提取物、红花提取物、当归提取物、玛咖提取物和甘草提取物按比例混合。
4.如权利要求3所述的可改善血液微循环障碍和骨质疏松症的天然组合物的制备方法,其特征在于:所述三七提取物的提取方法包括:取干燥三七,粉碎,与65~75%乙醇以质量体积比1:5~10的比例混合,浸润22~26h,70-90℃回流提取3~5小时,减压浓缩至浸膏,将所得浸膏干燥,即得三七提取物。
5.如权利要求3所述的可改善血液微循环障碍和骨质疏松症的天然组合物的制备方法,其特征在于:所述桃仁提取物的提取方法包括:取桃仁,粉碎,与乙醇以质量体积比1:5~10的比例混合,浸润2~4h,60-80℃回流提取4~5小时,减压浓缩至浸膏,所得浸膏干燥后即为桃仁提取物。
6.如权利要求3所述的可改善血液微循环障碍和骨质疏松症的天然组合物的制备方法,其特征在于:所述骨碎补提取物的提取方法包括:取干燥的骨碎补,粉碎,与蒸馏水以质量体积比1:10~20的比例混合,80~90℃浸泡提取4~8小时,水提取液减压浓缩至浸膏,浸膏与乙醇以质量体积比1:5~8的比例混合,收集沉淀物,沉淀物进行干燥后即可得骨碎补提取物。
7.如权利要求3所述的可改善血液微循环障碍和骨质疏松症的天然组合物的制备方法,其特征在于:所述红花提取物的提取方法包括:取红花,与蒸馏水以质量体积比1:30~40的比例混合,调节pH至2~4,70-90℃回流提取2~4小时,过滤,滤液减压蒸馏浓缩至浸膏状态,浸膏与乙醇以质量体积比1:5~10的比例混合,以1800~2200r/min离心8~12min,所得沉淀物真空干燥,即得红花提取物。
8.如权利要求3所述的可改善血液微循环障碍和骨质疏松症的天然组合物的制备方法,其特征在于:所述当归提取物的提取方法包括:取干燥的当归适量,粉碎,与水以质量体积比1:5~10的比例混合,70-90℃回流提取3~5小时,减压浓缩,加入乙醇至醇浓度为60~70%,放置22~26h抽滤后干燥即得当归提取物。
9.如权利要求3所述的可改善血液微循环障碍和骨质疏松症的天然组合物的制备方法,其特征在于:所述玛咖提取物的提取方法包括:取干燥的玛咖,与乙醇以质量体积比1:5~10的比例混合,超声提取2~4小时,醇提取液45~55℃减压浓缩至浸膏,浸膏干燥即得玛咖提取物;所述甘草提取物的提取方法包括:取干燥的甘草,与蒸馏水以质量体积比1:9~11的比例混合,88~92℃回流提取3.5~4.5小时,提取液浓缩至原体积的1/4~1/6,过滤,滤液加浓盐酸调pH至2~4,静置7~9小时,过滤,滤渣用蒸馏水洗涤,滤渣干燥即得甘草提取物。
10.权利要求1或2所述的可改善血液微循环障碍和骨质疏松症的天然组合物在制备改善血液微循环障碍并预防骨质疏松症药物中的应用,其特征在于:所述改善血液微循环障碍并预防骨质疏松症药物可用于降低血液粘度、提高血液流动性,增强骨组织中氧气和营养物质的运输能力,提高骨密度、骨矿物质含量。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910338442.XA CN110101756A (zh) | 2019-04-25 | 2019-04-25 | 一种可改善血液微循环障碍和骨质疏松症的天然组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910338442.XA CN110101756A (zh) | 2019-04-25 | 2019-04-25 | 一种可改善血液微循环障碍和骨质疏松症的天然组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110101756A true CN110101756A (zh) | 2019-08-09 |
Family
ID=67486738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910338442.XA Pending CN110101756A (zh) | 2019-04-25 | 2019-04-25 | 一种可改善血液微循环障碍和骨质疏松症的天然组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110101756A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7370653B1 (ja) * | 2023-05-10 | 2023-10-30 | Towa Corporation 株式会社 | エリスロポエチン遺伝子発現亢進用医薬組成物及び食品組成物 |
-
2019
- 2019-04-25 CN CN201910338442.XA patent/CN110101756A/zh active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7370653B1 (ja) * | 2023-05-10 | 2023-10-30 | Towa Corporation 株式会社 | エリスロポエチン遺伝子発現亢進用医薬組成物及び食品組成物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009543758A (ja) | 神経疾患および脳梗塞患者に対する治療のための併用療法 | |
KR100877604B1 (ko) | 가공인삼 추출물을 함유하는 비만의 예방 및 치료용조성물 | |
CN102145106B (zh) | 一种治疗骨质疏松症的中药组合物及补肾活血颗粒剂 | |
KR100585445B1 (ko) | 혼합 생약재를 이용한 골질환 예방 및 치료용 약제 조성물 | |
Tyagi et al. | Evaluation of antihyperlipidemic activity of ethanolic root extract of Glycyrrhiza glabra Linn. | |
CN108125999A (zh) | 一种辅助降血脂降血压的超微粉组合物及其制备方法与应用 | |
CN110101756A (zh) | 一种可改善血液微循环障碍和骨质疏松症的天然组合物及其制备方法 | |
CN1833686A (zh) | 一种纯中药降压药物 | |
CN103405755B (zh) | 一种治疗原发性骨质疏松症的药物组合物 | |
CN101695563A (zh) | 一种防治慢性气管炎肺心病的颗粒和散 | |
RU2328879C2 (ru) | Состав для приготовления биологически активной добавки к пище | |
CN1148213C (zh) | 用于治疗骨质疏松症的药物组合物 | |
US7641921B1 (en) | Anti-anal fistula composition and process for its manufacture | |
CN105943617A (zh) | 全麻素在制备抗肝炎药物中的应用 | |
CN110201041A (zh) | 一种活血化瘀通脉降脂的组合物 | |
CN105434797A (zh) | 一种养骨健身口服液及其制备方法 | |
CN108186920A (zh) | 一种具有辅助降血脂功效的药物组合物及其制备方法 | |
CN108902989A (zh) | 一种辅助改善心脑血管疾病的人参肽及其制备方法 | |
CN106853021A (zh) | 防治慢性肾脏病的中药组合物及其制备方法和应用 | |
Mungho et al. | Acute toxicity and antihypertensive effects of Artemisia afra and Leonotis leonurus in spontaneously hypertensive rats | |
CN100594918C (zh) | 一种治疗骨质疏松的中药复方口服制剂及其制备方法 | |
CN103768158A (zh) | 一种防治骨质疏松症的药物组合物及其制备方法 | |
CN105521036A (zh) | 降血压茶饮 | |
CN107343925B (zh) | 一种治疗慢性心力衰竭的中药组合物及其制备方法 | |
CN110237166A (zh) | 一种可改善肝功能并预防骨质疏松的天然组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190809 |